Stock Performance and Market Context
On the day, TruAlt Bioenergy’s stock price fell by 3.73% intraday, closing with a loss of 2.09%, underperforming the Commodity Chemicals sector by 0.75%. This decline extends a three-day losing streak, during which the stock has shed 7.45% of its value. The current price of Rs.364 represents both a new 52-week and all-time low, a notable drop from its 52-week high of Rs.550.
The stock is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling sustained downward momentum. In contrast, the Sensex opened lower at 83,435.31 points, down 0.17%, and is currently trading marginally down by 0.02% at 83,558.18. The Sensex remains 3.11% below its 52-week high of 86,159.02, with its 50-day moving average positioned above the 200-day moving average, indicating a relatively healthier market trend compared to TruAlt Bioenergy’s stock.
Financial Metrics and Fundamental Assessment
TruAlt Bioenergy’s financial indicators reveal ongoing difficulties. The company reported net sales of Rs.104.48 crores in the latest quarter, marking the lowest quarterly sales figure recorded. Operating profitability remains under pressure, with a PBDIT of negative Rs.11.79 crores and an operating profit to interest coverage ratio of -0.31 times, reflecting insufficient earnings to cover interest expenses.
The company’s return on capital employed (ROCE) is negative, underscoring the challenges in generating adequate returns from its capital base. Despite this, the company’s ROCE over the past year is noted at 8.9%, which, coupled with an enterprise value to capital employed ratio of 1.7, suggests an attractive valuation from a purely numerical standpoint. However, these figures contrast with the company’s weak long-term fundamental strength, as indicated by its strong sell Mojo Grade of 20.0, assigned on 17 Dec 2025.
This week's disclosed pick, a Large Cap from NBFC, comes with precise Target Price and analysis. Check if you're positioned right for this opportunity!
- - Precise target price set
- - Weekly selection live
- - Position check opportunity
Debt Profile and Institutional Holding Trends
TruAlt Bioenergy is classified as a high-debt company, although its average debt-to-equity ratio stands at zero times, suggesting limited reliance on equity financing. The company’s operating losses and negative returns on capital employed contribute to its cautious market standing.
Institutional investors have reduced their stake by 0.9% over the previous quarter, now collectively holding 8.2% of the company’s shares. This decline in institutional participation may reflect concerns about the company’s financial health and growth prospects, given these investors’ typically rigorous fundamental analysis capabilities.
Comparative Performance and Sectoral Context
Over the past year, TruAlt Bioenergy’s stock has generated a flat return of 0.00%, significantly lagging the Sensex’s 7.97% gain over the same period. Despite the stagnant stock price, the company’s profits have risen by 342%, indicating some operational improvements that have yet to translate into market confidence or share price appreciation.
The Commodity Chemicals sector, in which TruAlt Bioenergy operates, has generally outperformed the stock, with sectoral indices showing more resilience. The stock’s underperformance relative to its sector peers highlights the challenges it faces in regaining investor trust and market momentum.
Considering TruAlt Bioenergy? Wait! SwitchER has found potentially better options in Commodity Chemicals and beyond. Compare this small-cap with top-rated alternatives now!
- - Better options discovered
- - Commodity Chemicals + beyond scope
- - Top-rated alternatives ready
Mojo Score and Market Capitalisation Insights
TruAlt Bioenergy’s Mojo Score of 20.0 places it firmly in the Strong Sell category, reflecting the market’s assessment of its current financial and operational standing. This rating was assigned on 17 Dec 2025, marking a downgrade from its previous ungraded status. The company’s market capitalisation grade is rated at 3, indicating a relatively modest market value compared to peers in the Commodity Chemicals sector.
The combination of a low Mojo Score and a weak market cap grade underscores the challenges the company faces in attracting positive market sentiment and institutional support.
Summary of Key Financial Indicators
To summarise, TruAlt Bioenergy’s key financial metrics for the latest quarter include:
- Net Sales: Rs.104.48 crores (lowest quarterly figure)
- PBDIT: Negative Rs.11.79 crores
- Operating Profit to Interest Coverage: -0.31 times
- Debt to Equity Ratio (average): 0 times
- ROCE: Negative in recent quarters, but 8.9% over the past year
- Enterprise Value to Capital Employed: 1.7
These figures illustrate the company’s current financial strain, despite some positive valuation metrics.
Conclusion
TruAlt Bioenergy’s fall to a 52-week low of Rs.364 reflects a confluence of factors including weak quarterly sales, negative profitability, and reduced institutional participation. The stock’s underperformance relative to the Sensex and its sector peers highlights ongoing challenges in regaining market confidence. While certain valuation metrics appear attractive, the company’s overall fundamental strength remains subdued as reflected in its Strong Sell Mojo Grade and recent financial results.
Unlock special upgrade rates for a limited period. Start Saving Now →
